HIMS & HERS HEALTH INC (HIMS) Stock News
NYSE:HIMS - New York Stock Exchange, Inc. - US4330001060 - Common Stock - Currency: USD
HIMS Latest News, Press Relases and Analysis
HIMS & HERS HEALTH INC (NYSE:HIMS) – A Strong Growth Stock Meeting Minervini’s Criteria
HIMS & HERS HEALTH INC (NYSE:HIMS) is a high-growth telehealth stock meeting Minervini’s Trend Template with strong earnings, revenue growth, and bullish technicals.
These stocks are making the most noise in today's session.
Let's dive into the action on the US markets on Tuesday. Here are the most active stocks that are driving the market today.
These 24 Stocks Are Ripe for a Short Squeeze
Growth stocks tend to be heavily-shorted dart throws
Hims & Hers Stock Falls After Eli Lilly Rules Out Telehealth Tie-Up: Citi Calls It Aggressive Stance, Retail Turns Bearish
If Hims were to align with Lilly, Citi warned, it would signal the company has "thrown in the towel" on compounded medications.
Mentions: LLY
Should You Buy Eli Lilly Stock Before June 22?
Eli Lilly will be presenting data from studies on multiple GLP-1 drugs later this month. Eli Lilly (NYSE: LLY) stock hasn't been doing too well this year, but that could change later this month. If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs.
Lilly Pacts Bar Telehealth Firms From Selling Copycat Zepbound
Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, diminishing the likelihood of a partnership with one most visible players in the industry, Hims & Hers Health Inc.
Mentions: LLY
Analysis: Hims & Hers says its weight-loss business can grow as US market changes
(Reuters) -Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some analysts see a need for the online website to adjust to changing competition in the U.S. Hims has thrived in the market for cheaper compounded versions of highly in-demand weight-loss drugs, such as Novo Nordisk's Wegovy. This was allowed by the U.S. Food and Drug Administration when those drugs were in shortage.
PEN Stock Rises Following the Launch of Ruby XL System
Penumbra launches FDA-cleared Ruby XL System to bring advanced coil technology to high-flow embolization procedures.
Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?
Mentions: NVO
Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?
Hims & Hers stock is on the upswing after the company secured a weight-loss drug partnership. Hims & Hers is acquiring its way into Europe and wants to build more personalized drugs for its telehealth customers. Many companies have failed to disrupt the complicated U.S. healthcare market.
Is Hims & Hers Health a Smart Buy Right Now?
Shares of Hims & Hers have crushed the market over the last year.
Is Hims & Hers Health a Smart Buy Right Now?
Shares of Hims & Hers have crushed the market over the last year.
This Monster Growth Stock Is Up 167% in the Past Year and Disrupting the Healthcare Space
Hims & Hers is gaining market share in the telehealth sector and has a long runway to disrupt the healthcare industry. One promising stock emerging from the bust is Hims & Hers (NYSE: HIMS). Disruptive innovation helped bring shareholders of Hims & Hers stock major gains.
HIMS' Buyouts Fuel International Expansion & Digital Health Innovation
Hims & Hers accelerates European growth with new ZAVA acquisition, adding localized care and lab testing innovation.
Omnicell (OMCL) Up 27% Since Last Earnings Report: Can It Continue?
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mentions: OMCL
Should You Continue to Hold EXAS Sciences Stock in Your Portfolio?
EXAS rides on strong Cologuard and Oncotype DX growth, but rising costs and high debt may test its staying power.
Hims & Hers Stock: Buy the Dip or Wait It Out?
Hims & Hers stock is giving up some gains after announcing the acquisition of Zava, a European digital healthcare platform.
HIMS Stock Falls Despite Latest Deal to Expand International Footprint
Hims & Hers is set to acquire ZAVA to launch in Germany, France and Ireland, deepening its personalized digital health push.
Why Is Hims & Hers Health (HIMS) Up 10.6% Since Last Earnings Report?
Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FactSet Stock Drops on News of CEO's Retirement Plan
Shares of FactSet Research Systems fell Tuesday after the financial data provider announced CEO Phil Snow will be retiring in September.
Top Stock Movers Now: Dollar General, Hims & Hers, Bumble, and More
U.S. equities were higher at midday as the market sought clarity on U.S. trade negotiations.
Hims & Hers To Acquire European Telehealth Brand Zava As It Looks To Expand Globally
The Zava acquisition will enable Hims & Hers to expand its footprint in the U.K. and launch operations in countries such as Germany, France, and Ireland, with other markets expected to follow soon.
IBD 50's Hims & Hers Health Shoots Higher On A Key Takeover In Europe
The company hopes the deal will help it snag business in the UK, building a similar model to its U.S. platform.
Mentions: LLY